with every breath
Across the UK, Europe, North American and Japan there are nearly 200 million smokers. More than 60 percent of smokers prefer to move beyond their smoking dependence. Yet they reject the current alternatives to do just that.
We believe there is an opportunity to create a new category of medically approved products that much closer match the session-based experience of smokers, at a medical standard free of the excipients that vapers want.
Smoking dependence begins usually as a ritual,
and a pleasure. But for many it soon becomes
a dependence. The majority of smokers wish to
move beyond this reliance. We are working on just
such a medically approved platform, that has the
session-based ritual of analogue cigarettes, and
the safety of a medically approved product.
Smoking dependence begins usually as a ritual, and a pleasure. But for many it soon becomes a dependence. The majority of smokers wish to move beyond this reliance. We are working on just such a medically approved platform, that has the session-based ritual of analogue cigarettes, and the safety of a medically approved product.
ENHALE by VENTUS
Electronic cigarettes and vaporisers reduce the harm significantly, but are not without risks. They can be the source of a new grazing habit, where the user has no context of quantum of nicotine consumed leading to increased dependency.
Our ambition is to provide a medically approved platform, that makes it possible for smokers to move beyond tobacco, and eliminate the grazing and excipient risk of uncontrolled vaping.
The majority of smokers wish to quit.
They are aware of the existing alternatives, but prefer to smoke than adopt any. They understand that smoking is harmmful, but either reject or fail to quit with current medically approved offerings.
There’s an unmet need for a medically approved platform that is familiar to the single session-based ritual of smoking.
Neither a gum, nor a patch, nor a spray, not a grazing stick provide that arc of use, the finite beginning and end, that a smoking ritual offers its users. We have been thinking of just such a product. The authority of a medically approved product. The familiarity of a session based experience. This is not nicotine replacement therapy. This is ENHALE.
We have been working on the science of inhalation for nearly ten years.
We were the inventors and scientists who secured medical approval for the first electronic nicotine delivery system from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK
We are working on the technology to enable a new generation of smoking cessation.
ENHALE, the first in our product pipeline of medical developments, has been CE marked as a medical device in the European Union under the Medical Devices Directive and is currently in development for clinical studies to support its marketing authorisation within Europe.
Extensive research into nicotine delivery, stability and aerosol science has enabled this new generation of products designed for a truly safe and effective platform for smoking cessation.
Certified to; ISO 13485: MD 685247, ISO 14001: EMS 722404, & ISO 9001: 724473
As an inhalation company we are evolving our technology to safely deliver medicines to the lung.
Our founding team and executive management are pioneers in next-generation inhalation and medical technologies.
We are biochemists, engineers, clinicians and researchers.
But perhaps most importantly, we all have people in our lives who have been touched and struggled with smoking.